Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 79

1.

Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.

van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Roos WK, Linn SC, Imholz ALT, de Boer M, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Breast Cancer Res Treat. 2020 Apr;180(3):675-685. doi: 10.1007/s10549-020-05567-9. Epub 2020 Mar 2.

2.

The trans-DATA study: aims and design of a translational breast cancer prognostic marker identification study.

de Ruijter TC, Smits KM, Aarts MJ, van Hellemond IEG, Van Neste L, de Vries B, Peer PGM, Veeck J, van Engeland M, Tjan-Heijnen VCG.

Diagn Progn Res. 2019 Oct 17;3:20. doi: 10.1186/s41512-019-0065-6. eCollection 2019.

3.

Assessment and management of bone health in women with early breast cancer receiving endocrine treatment in the DATA study.

van Hellemond IEG, Smorenburg CH, Peer PGM, Swinkels ACP, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Int J Cancer. 2019 Sep 1;145(5):1325-1333. doi: 10.1002/ijc.32205. Epub 2019 Mar 4.

4.

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy-induced ovarian function failure.

van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Int J Cancer. 2019 Jul 1;145(1):274-283. doi: 10.1002/ijc.32093. Epub 2019 Jan 16.

5.

Paediatric Ebstein's anomaly: how clinical presentation predicts mortality.

Geerdink LM, Delhaas T, Helbing WA, du Marchie Sarvaas GJ, Heide HT, Rozendaal L, de Korte CL, Peer PGM, Kuipers IM, Kapusta L.

Arch Dis Child. 2018 Sep;103(9):859-863. doi: 10.1136/archdischild-2017-313482. Epub 2018 Mar 22.

PMID:
29567665
6.

Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.

van Hellemond IEG, Vriens IJH, Peer PGM, Swinkels ACP, Smorenburg CH, Seynaeve CM, van der Sangen MJC, Kroep JR, de Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, Kitzen JJEM, de Boer M, de Roos WK, Linn SC, Imholz ALT, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx074.

PMID:
29546343
7.

Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.

Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators.

Lancet Oncol. 2017 Nov;18(11):1502-1511. doi: 10.1016/S1470-2045(17)30600-9. Epub 2017 Oct 12. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642.

PMID:
29031778
8.

Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer.

Vriens BEPJ, Vriens IJH, Aarts MJB, van Gastel SM, van den Berkmortel FWPJ, Smilde TJ, van Warmerdam LJC, van Spronsen DJ, Peer PGM, de Boer M, Tjan-Heijnen VCG; Breast Cancer Trialists’ Group of the Netherlands (BOOG).

Breast Cancer Res Treat. 2017 Oct;165(3):593-600. doi: 10.1007/s10549-017-4364-8. Epub 2017 Jul 3.

9.

Axillary staging in breast cancer patients treated with neoadjuvant chemotherapy in two Dutch phase III studies.

Vriens BEPJ, Keymeulen KBMI, Kroep JR, Charehbili A, Peer PG, de Boer M, Aarts MJB, Heuts EM, Tjan-Heijnen VCG; Dutch Breast Cancer Research Group (BOOG).

Oncotarget. 2017 Jul 11;8(28):46557-46564. doi: 10.18632/oncotarget.15101.

10.

Growth rate of invasive ductal carcinomas from a screened 50-74-year-old population.

Otten JD, van Schoor G, Peer PG, den Heeten GJ, Holland R, Broeders MJ, Verbeek AL.

J Med Screen. 2018 Mar;25(1):40-46. doi: 10.1177/0969141316687791. Epub 2017 Jan 13.

PMID:
28084888
11.

Impact of chemotherapy on the outcome of osteosarcoma of the head and neck in adults.

Boon E, van der Graaf WT, Gelderblom H, Tesselaar ME, van Es RJ, Oosting SF, de Bree R, van Meerten E, Hoeben A, Smeele LE, Willems SM, Witjes MJ, Buter J, Baatenburg de Jong RJ, Flucke UE, Peer PG, Bovée JV, Van Herpen CM.

Head Neck. 2017 Jan;39(1):140-146. doi: 10.1002/hed.24556. Epub 2016 Aug 10.

12.

Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.

Seferina SC, de Boer M, Derksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, Joore M, Peer PG, Voogd AC, Tjan-Heijnen VC.

Oncologist. 2016 May;21(5):555-62. doi: 10.1634/theoncologist.2015-0230. Epub 2016 Mar 23.

13.

Ultrasound is at least as good as magnetic resonance imaging in predicting tumour size post-neoadjuvant chemotherapy in breast cancer.

Vriens BE, de Vries B, Lobbes MB, van Gastel SM, van den Berkmortel FW, Smilde TJ, van Warmerdam LJ, de Boer M, van Spronsen DJ, Smidt ML, Peer PG, Aarts MJ, Tjan-Heijnen VC; INTENS Study Group.

Eur J Cancer. 2016 Jan;52:67-76. doi: 10.1016/j.ejca.2015.10.010. Epub 2015 Nov 30.

PMID:
26650831
14.

In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium.

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC.

Ann Oncol. 2016 Feb;27(2):256-62. doi: 10.1093/annonc/mdv544. Epub 2015 Nov 16.

15.

Real-Life Use and Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer Patients: A Study of the Southeast Netherlands Breast Cancer Consortium.

Seferina SC, Lobbezoo DJ, de Boer M, Dercksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, de Vries B, Joore MA, Peer PG, Voogd AC, Tjan-Heijnen VC.

Oncologist. 2015 Aug;20(8):856-63. doi: 10.1634/theoncologist.2015-0006. Epub 2015 Jun 22.

16.

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC.

Br J Cancer. 2015 Apr 28;112(9):1445-51. doi: 10.1038/bjc.2015.127. Epub 2015 Apr 16.

17.

A Retrospective Cohort Study on the Influence of Comorbidity on Soft Tissue Reactions, Revision Surgery, and Implant Loss in Bone-anchored Hearing Implants.

den Besten CA, Nelissen RC, Peer PG, Faber HT, Dun CA, de Wolf MJ, Kunst HP, Cremers CW, Mylanus EA, Hol MK.

Otol Neurotol. 2015 Jun;36(5):812-8. doi: 10.1097/MAO.0000000000000745.

PMID:
25811351
18.

Annexin A5 haplotypes in familial hypercholesterolemia: lack of association with carotid intima-media thickness and cardiovascular disease risk.

Hiddink L, Dallinga-Thie GM, Hovingh GK, de Visser MC, Peer PG, Stalenhoef AF, van Heerde WL.

Atherosclerosis. 2015 Feb;238(2):195-200. doi: 10.1016/j.atherosclerosis.2014.11.023. Epub 2014 Nov 29.

PMID:
25525746
19.

Nationwide inventory of risk factors for retinopathy of prematurity in the Netherlands.

van Sorge AJ, Termote JU, Kerkhoff FT, van Rijn LJ, Simonsz HJ, Peer PG, Schalij-Delfos NE.

J Pediatr. 2014 Mar;164(3):494-498.e1. doi: 10.1016/j.jpeds.2013.11.015. Epub 2013 Dec 19.

PMID:
24360994
20.

A simple risk score to predict the presence of non-sentinel lymph node metastases in breast cancer patients with a positive sentinel node.

van la Parra RF, Peer PG, de Roos WK, Ernst MF, de Wilt JH, Bosscha K.

World J Surg. 2014 May;38(5):1070-6. doi: 10.1007/s00268-013-2387-9.

PMID:
24305938

Supplemental Content

Loading ...
Support Center